Quantcast
Last updated on April 21, 2014 at 5:21 EDT

ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2

December 2, 2010

IRVINE, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ — ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in phytochemical reference standards and related contract analysis and research services, today announced that it has entered into a global agreement with Kappa Bioscience AS (Oslo, Norway) to supply analytical reference standards, quality control methods and related analytical testing services for Vitamin K2, Menaquinone-7(MK-7) in raw materials and finished goods.

“With increasing market demand for Vitamin K2 MK-7, there will be an increase in demand for reference standards, quality control methods, research tools and analytical services,” said Frank Jaksch, CEO and co-founder of ChromaDex. “Since MK-7 is a vitamin product manufactured from different sources, it is critical that testing procedures are in place to ensure the quality and consistency of any MK-7 related ingredient or product.”

Vitamin K2 is shown to have significant importance for optimal utilization of calcium in the body related to bone and cardiovascular health. Studies indicate that the Western diet is deficient in Vitamin K2. Thus, daily supplementation is expected to be beneficial for the bone building process as well as for cardiovascular health.

“The market needs a reliable and impartial third party expert like ChromaDex to bring clarity to Vitamin K analysis,” said Egil Greve, CEO of Kappa Bioscience. “To date it has been difficult, if not impossible, to verify the label claims of Vitamin K2 in nutritional products. We expect that industry interest and confidence in Vitamin K2 will grow now that we can all confirm fortification,” he added.

About ChromaDex

ChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable “green chemistry” and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. The company has worldwide exclusive patent rights related to pterostilbene. For more information, visit http://www.chromadex.com/ or follow ChromaDex on Twitter @ChromaDex.

About Kappa Bioscience

Kappa Bioscience is the innovative leader and first mover with high purity vitamin K2 as menaquinone-7 (MK-7). Kappa Bioscience is a Norwegian based entity with substantial resources and knowledge about vitamins and vitamin K2 in particular. Kappa Bioscience is currently the only vendor with vitamin K2 as pure MK-7 in various formulations, following a traditional vitamin production process with proprietary and innovative new steps. The company is operating in the US through Xsto Solutions and has its manufacturing in NJ, USA. For further information, visit http://www.kappabio.com


    CHROMADEX CONTACTS

    Investor Inquiries
    Liviakis Financial Communications, Inc.
    John M. Liviakis, President
    415-389-4670
    John@Liviakis.com

    ChromaDex Contact
    Jenny Robles
    Administrative Assistant to the CEO
    10005 Muirlands Blvd, Suite G, Irvine, CA 92618
    949-419-0288
    jennyr@chromadex.com

    Media Contact
    Megan Lavine
    Canale Communications
    3033 5th Ave., Suite 400, San Diego, CA 92103
    619-849-5388
    megan@canalecomm.com

    KAPPA BIOSCIENCE CONTACTS
    Egil Greve
    Chief Executive Officer
    +47 95 10 9565
    egil.greve@kappabio.com

    Arne Johan Grimsbo
    VP Strategy & Bus. Dev
    +47 90 984824
    arne.grimsbo@kappabio.com

SOURCE ChromaDex Corporation


Source: newswire